[1] |
World Health Organization. Global tuberculosis report 2021[EB/OL]. World Health Organization2021.
URL
|
[2] |
Oku K, Hamijoyo L, Kasitanon N, et al. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements[J]. Int J Rheum Dis,2021,24(7):880-895.
|
[3] |
Pego-Reigosa JM, Nicholson L, Pooley N, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis[J]. Rheumatology (Oxford),2021,60(1):60-72.
|
[4] |
Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection[J]. Expert Rev Clin Immunol,2020,16(5):527-538.
|
[5] |
穆克利. 系统性红斑狼疮患者感染结核分枝杆菌后血清免疫指标变化及临床意义 [J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(5):627-630.
|
[6] |
Doaty S, Agrawal H, Bauer E, et al. Infection and lupus: which causes which?[J]. Curr Rheumatol Rep,2016,18(3):13.
|
[7] |
González-Naranjo LA, Coral-Enríquez JA, Restrepo-Escobar M, et al. Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study[J]. Clin Rheumatol,2021,40(1):181-191.
|
[8] |
Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients[J]. Rheum Dis Clin North Am,2014,40(3):507-17, viii.
|
[9] |
Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials[J]. Autoimmun Rev,2018,17(8):781-790.
|
[10] |
全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志,2012,34(8):485-508.
|
[11] |
Liu X, Zhang L, Zhang F, et al. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China[J]. Emerg Microbes Infect,2021,10(1):2303-2312.
|
[12] |
Xiao X, Da G, Xie X, et al. Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study[J]. J Intern Med,2021,290(1):101-115.
|
[13] |
Lao M, Chen D, Wu X, et al. Active tuberculosis in patients with systemic lupus erythematosus from Southern China: a retrospective study[J]. Clin Rheumatol,2019,38(2):535-543.
|
[14] |
Muhammed H, Jain A, Pattanaik SS, et al. Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus[J]. Rheumatol Int,2021,41(12):2185-2193.
|
[15] |
Hamijoyo L, Candrianita S, Rahmadi A R, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital[J]. Lupus,2019,28(13):1604-1609.
|
[16] |
Cheng CF, Huang YM, Lu CH, et al. Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study[J]. Lupus,2019,28(14):1699-1704.
|
[17] |
Greenstein L, Makan K, Tikly M. Burden of comorbidities in South Africans with systemic lupus erythematosus[J]. Clin Rheumatol,2019,38(8):2077-2082.
|
[18] |
Yang Y, Thumboo J, Tan BH, et al. The risk of tuberculosis in SLE patients from an Asian tertiary hospital[J]. Rheumatol Int,2017,37(6):1027-1033.
|
[19] |
中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288-2017)[J/CD]. 新发传染病电子杂志,2018,3(1):59-61.
|
[20] |
Sargin G, Senturk T, Ceylan E, et al. TST, QuantiFERON-TB Gold test and T-SPOT. TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy[J]. Tuberk Toraks,2018,66(2):136-143.
|
[21] |
边赛男, 刘晓清. γ-干扰素释放试验在免疫功能抑制人群中诊断结核分枝杆菌感染的应用[J/CD]. 中华实验和临床感染病杂志(电子版)2017,11(2):117-120.
|
[22] |
Zhang L, Zhang Y, Shi X, et al. Utility of T-cell interferon-gamma release assays for diagnosing tuberculous serositis: a prospective study in Beijing, China[J]. PLoS One,2014,9(1):e85030.
|
[23] |
Palavutitotai N, Buppajarntham T, Katchamart W. Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus[J]. J Clin Rheumatol,2014,20(8):418-421.
|
[24] |
Chen DY, Huang YH, Chen YM, et al. ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies[J]. Lupus Sci Med,2021,8(1):e000562.
|
[25] |
Silva JE, Silva C, Pacheco M, et al. Simultaneous systemic lupus erythematosus flare and disseminated tuberculosis: Balancing anti-mycobacterial and autoimmune treatments[J]. Cureus,2021,13(10):e18944.
|
[26] |
World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management[M]. Geneva, 2018.
|
[27] |
国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知[EB/OL]. (2020-04-02) [2020-06-10].
URL
|
[28] |
中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志,2021,43(9):874-878.
|
[29] |
Gaitonde S, Pathan E, Sule A, et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment [J]. Ann Rheum Dis,2002,61(3):251-253.
|
[30] |
马丽, 林冰, 王丽英, 等. 预防治疗系统性红斑狼疮患者医源性活动性结核病的临床观察 [J]. 中华医学杂志,2014,45(4):3579-3582.
|
[31] |
Mok MY, Lo Y, Chan TM, et al. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy[J]. J Rheumatol,2005,32(4): 609-615.
|
[32] |
谢其冰, 尹耕. 应用异烟肼预防系统性红斑狼疮患者结核感染的作用评估[J]. 四川大学学报(医学版),2008,39(3):519-520.
|
[33] |
赵利军, 刘桂枝. 异烟肼预防系统性红斑狼疮患者结核感染的临床分析[J]. 世界最新医学信息文摘,2015,15(98):74-75.
|